The majority of the studies assessed the impact of SGLT2 in HFrEF patients, while a smaller subset analyzed its efficacy in HFpEF and HF with mid-range ejection fraction (HFmrEF, LVEF 40–49%). The gene discussed is SLC5A2; the disease is hydrops fetalis.